Craniotomy and craniectomy are sometimes discussed as though they were interchangeable procedures. They are not.
Both operations involve creating or removing a section of the skull to provide surgical access to the brain. The defining difference is what happens to the bone flap before the initial operation is completed: a craniotomy replaces the bone flap, while a craniectomy does not.
That distinction affects more than terminology. It changes the reconstruction pathway, the anatomy encountered during closure, and the likelihood that the patient will require a subsequent cranial procedure. It also provides important context for understanding where a protective biologic graft may—and may not—fit within cranial surgery.
What is a craniotomy?
A craniotomy is a surgical procedure in which a section of skull, commonly called a bone flap, is temporarily removed to provide access to the intracranial space. After the planned work is completed, the bone flap is returned to its original position and typically secured with cranial fixation hardware.
Craniotomy may be performed for a wide range of indications, including the treatment of tumors, aneurysms, vascular abnormalities, hematomas, epilepsy, trauma, and other neurologic conditions.
The exact approach and closure vary with the indication, anatomy, surgeon preference, and condition of the surrounding tissues. However, replacement of the bone flap during the same operation is the feature that distinguishes a craniotomy from a craniectomy.
What is a craniectomy?
A craniectomy also involves removal of a section of skull, but the bone flap is not replaced during the initial operation.
One well-known example is decompressive craniectomy, which may be performed to give a swollen brain additional room and help manage refractory intracranial pressure. A craniectomy may also be necessary when the bone is contaminated, infected, damaged, or otherwise unsuitable for immediate replacement.
Because the cranial defect remains after the operation, many patients later undergo a separate procedure called cranioplasty. During cranioplasty, the defect is reconstructed using the patient’s preserved bone flap or an implant made from another material.
Craniotomy vs. craniectomy at a glance
| Consideration | Craniotomy | Craniectomy |
|---|---|---|
| Bone flap | Temporarily removed | Removed and left off |
| End of initial procedure | Bone flap replaced and secured | Cranial defect remains |
| Common purpose | Surgical access to intracranial anatomy | Surgical access and, in selected cases, decompression |
| Later cranial reconstruction | Generally not required solely because of the opening | Cranioplasty is commonly considered later |
| Future re-entry | Depends on the underlying condition | Often anticipated when staged cranioplasty is planned |
The patient’s underlying disease, neurologic status, intracranial pressure, contamination risk, tissue condition, and overall treatment plan determine which operation is appropriate. The terminology should describe what occurred; it should not be used as a shortcut for judging the complexity or urgency of the case.
Why tissue planes matter in cranial surgery
Cranial operations require surgeons to move through several distinct anatomical layers, including the scalp, connective tissue, muscle or fascia depending on the approach, skull, and dura.
Healing naturally begins after these tissues are manipulated. That response is necessary, but it can also alter the planes encountered if the area must be entered again. Scar formation and adherence between adjacent tissues may make later exposure more technically demanding.
This consideration is particularly relevant when another operation is already part of the treatment pathway, as may occur with staged cranioplasty after decompressive craniectomy. It can also matter in patients whose underlying condition creates a possibility of future cranial surgery.
The surgeon’s first priorities remain secure closure, protection of intracranial structures, infection prevention, management of cerebrospinal fluid, and restoration of appropriate anatomy. Within that broader plan, the treatment of exposed tissue surfaces and the relationship between adjacent tissue planes may also warrant consideration.
Where a protective biologic graft may fit
Some human placental tissue allografts are supplied as thin sheets that provide a biocompatible extracellular matrix and may be used as protective barriers over exposed tissue when the application is consistent with the product’s instructions for use.
In a cranial procedure, the proposed role is best understood as an onlay protective interface within the closure—not as a structural implant and not as a replacement for standard surgical technique.
Depending on the specific product, its instructions for use, and the clinical circumstances, a surgeon may evaluate an allograft for placement over an exposed tissue surface before completing the remaining layers of closure. Product selection and placement must remain case-specific.
Several boundaries are essential:
- A protective placental allograft should not be described as replacing the cranial bone flap or a patient-specific cranial implant.
- It should not be described as providing rigid structural reconstruction.
- It should not be represented as repairing the dura or serving as a dura substitute unless the specific product is expressly intended for that purpose.
- It should not be promoted as preventing adhesions, complications, or reoperation unless those claims are supported by the applicable product labeling and adequate clinical evidence.
For example, MIMEDX expressly states that AMNIOFIX is not intended to repair dura mater and is not intended as a dura substitute. That limitation should remain clear whenever the product is discussed in a neurosurgical setting.
What are placental tissue allografts?
Placental tissue contains a native extracellular matrix composed of structural proteins and other matrix-associated components. After donor screening, recovery, processing, preservation, testing, and packaging, qualifying tissue may be distributed as a human cell, tissue, or cellular or tissue-based product, depending on the product and its regulatory status.
The phrase “amniotic graft” is often used broadly, but products can differ materially. They may contain amnion, chorion, umbilical tissue, or combinations of placental layers. They may also differ in processing method, thickness, configuration, orientation, sterility assurance, storage requirements, handling, and intended use.
Those differences matter. A general discussion of placental tissue cannot substitute for review of the exact product’s labeling and instructions for use.
Practical questions for the surgical team
Before introducing any tissue allograft into a cranial program, the surgeon, operating-room team, tissue bank, infection-prevention personnel, value-analysis committee, and other hospital stakeholders may need to address several practical questions.
1. What is the intended function?
The clinical team should define the purpose of the graft precisely. “Protective barrier over exposed tissue” is materially different from dural repair, bone reconstruction, hemostasis, or treatment of an established complication.
2. Is the proposed use consistent with the instructions for use?
The team should review the manufacturer’s current instructions for use, contraindications, warnings, preparation requirements, and tissue-use statements. Marketing shorthand should never replace the controlling product documentation.
3. What configuration fits the anatomy?
Sheet dimensions, thickness, handling characteristics, orientation, and the ability to conform to the intended surface all affect product selection. The graft should be chosen for the actual anatomical area rather than by habit.
4. How is the tissue stored and tracked?
Hospitals need appropriate receiving, storage, chain-of-custody, traceability, and implantation-documentation procedures. The tissue identification information supplied with the allograft should be incorporated into the patient’s record according to institutional policy.
5. What evidence supports the proposed application?
The clinical evidence for placental allografts varies significantly by product and surgical specialty. Evidence from wound care or another anatomical application should not automatically be treated as proof of a clinical outcome in cranial surgery.
That is particularly important for claims involving adhesion reduction, easier surgical re-entry, infection, cerebrospinal-fluid leakage, healing time, or other patient outcomes. These questions require product-specific evidence and careful clinical judgment.
A developing area—not a replacement for established cranial technique
Biologic materials are increasingly part of conversations about how surgeons cover, protect, reinforce, or separate vulnerable tissues. Cranial surgery is a logical area for continued evaluation because tissue protection and, in some cases, future surgical access can both be important.
But scientific interest should not be confused with established clinical proof.
The central difference between craniotomy and craniectomy remains straightforward: the bone flap is replaced after a craniotomy and left off after a craniectomy. The possible role of a placental tissue allograft is narrower. When permitted by its instructions for use, it may serve as a protective onlay over exposed tissue as one component of a surgeon’s closure strategy.
It does not replace the fundamentals of neurosurgical closure, dural management, cranial fixation, cranioplasty, sterile technique, or sound clinical judgment.
Frequently asked questions
Is a craniotomy the same as a craniectomy?
No. In a craniotomy, the bone flap is replaced during the same operation. In a craniectomy, it is not replaced during the initial operation.
Does every craniectomy require a later cranioplasty?
Not every patient follows the same pathway, but cranioplasty is commonly considered after craniectomy to reconstruct the cranial defect when the patient’s condition and treatment plan permit it.
Is an amniotic or placental allograft a dura substitute?
Not necessarily. Intended uses differ by product. AMNIOFIX, for example, is not intended to repair dura mater and is not intended as a dura substitute. Clinicians must review the current instructions for use for the exact product being considered.
Can a placental allograft replace a cranial implant?
No. A thin placental tissue allograft does not provide the rigid structural reconstruction supplied by native bone or a cranial implant.
Are biologic grafts standard of care in cranial surgery?
Their use depends on the specific material, intended function, available evidence, surgeon judgment, and hospital policy. A broad claim that biologic grafts are standard of care in cranial surgery would not be appropriate.
Learn more
6|Sixty Biologics works with surgical teams and hospitals evaluating advanced tissue technologies for appropriate surgical applications. To discuss product specifications, hospital review, or clinical education, contact the 6|Sixty team.
For more about 6|Sixty, visit https://6sixty.com
Editorial and compliance note
This article is for educational purposes only and is not medical advice or a substitute for a product’s instructions for use, institutional policy, or independent clinical judgment. Product indications, warnings, contraindications, and regulatory status should be verified from current manufacturer and regulatory documentation before use.
References
- Munakomi S, Das JM. Craniotomy. StatPearls Publishing. PubMed record: https://pubmed.ncbi.nlm.nih.gov/32809757/
- Hutchinson PJ, et al. Decompressive Craniectomy versus Craniotomy for Acute Subdural Hematoma. New England Journal of Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/37092792/
- MIMEDX. Allograft Protective Barriers in Spine and Neurosurgery. https://www.mimedx.com/spine-and-neurosurgery/
- U.S. Food and Drug Administration. Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. https://www.fda.gov/media/109176/download
